1.Tsuchiya Y, Sawada S, Yoshioka I, Ohashi Y, Matsuo M, Harimaya Y, et al. Increased surgical stress promotes tumor metastasis. Surgery. 2003;133(5):547-55.
2.Acheson A G, Brookes M J, Spahn D R. Effects of allogeneic red blood cell transfusions on clinical outcomes in patients undergoing colorectal cancer surgery: a systematic review and meta-analysis. Annals of surgery. 2012;256(2):235-244.
3.Tavare A N, Perry N J S, Benzonana L L, Takata M, Ma D. Cancer recurrence after surgery: direct and indirect effects of anesthetic agents. International journal of cancer. 2012;130(6):1237-1250.
4. Fodale V, D’Arrigo M G, Triolo S, Mondello S, La Torre D. Anesthetic techniques and cancer recurrence after surgery. ScientificWorldJournal. 2014;2014:328513.
5. Mirabella L, Bellanti F, Tullo L, Serviddio G, Cinnella G, Dambrosio M. Effect of sevoflurane and propofol anaesthesia on mitochondria and postoperative hepatocellular injury in steatotic patients: preliminary data: 9AP5-7. European Journal of Anaesthesiology. 2013;30:153-153.
6. Ren XF, Li WZ, Meng FY, Lin CF. Differential effects of propofol and isoflurane on the activation of T-helper cells in lung cancer patients. Anaesthesia. 2010;65:478-482.
7. Herling SF, Dreijer B, Lam GW, Thomsen T, Møller AM. Total intravenous anaesthesia versus inhalational anaesthesia for adults undergoing transabdominal robotic assisted laparoscopic surgery. Cochrane Database of Systematic Reviews. 2017;(4).
8. Benzonana LL, Perry NJ, Watts HR, Yang B, Perry IA, Coombes C, et al. Isoflurane, a commonly used volatile anesthetic, enhances renal cancer growth and malignant potential via the hypoxia-inducible factor cellular signaling pathway in vitro. Anesthesiology. 2013;119:593-605.
9. Loop T, Dovi-Akue D, Frick M, Roesslein M, Egger L, Humar M, et al. Volatile anesthetics induce caspase-dependent, mitochondria-mediated apoptosis in human T lymphocytes in vitro. Anesthesiology. 2005;102:1147-57
10. Zhang D, Zhou XH, Zhang J, Zhou YX, Ying J, Wu GQ, et al. Propofol promotes cell apoptosis via inhibiting HOTAIR mediated mTOR pathway in cervical cancer. Biochemical and biophysical research communications. 2015;468(4):561-567.
11. Song J, Shen Y, Zhang J, Lian Q. Mini profile of potential anticancer properties of propofol. PLoS One 2014;9:e114440.
12. Yang C, Gao J, Yan N, Wu B, Ren Y, Li H, Liang J. Propofol inhibits the growth and survival of gastric cancer cells in vitro through the upregulation of ING3. Oncol Rep. 2017;37:587-593.
13. Kushida A, Inada T, Shingu K. Enhancement of antitumor immunity after propofol treatment in mice. Immunopharmacol Immunotoxicol. 2007;29:477-86
14. Enlund M, Berglund A, Andreasson K, Cicek C, Enlund A, Bergkvist L. The choice of anaesthetic—sevoflurane or propofol—and outcome from cancer surgery: a retrospective analysis. Upsala journal of medical sciences. 2014;119(3):251-261.
15. Wigmore T J, Mohammed K, Jhanji S. Long-term Survival for Patients Undergoing Volatile versus IV Anesthesia for Cancer SurgeryA Retrospective Analysis. Anesthesiology. 2016;124(1):69-79.
16. Lee JH, Kang SH, Kim Y, Kim HA, Kim BS. Effects of propofol-based total intravenous anesthesia on recurrence and overall survival in patients after modified radical mastectomy: a retrospective study. Korean journal of anesthesiology. 2016;69(2):126-132.
17. Kim MH, Kim DW, Kim JH, Lee KY, Park S, Yoo YC. Does the type of anesthesia really affect the recurrence-free survival after breast cancer surgery? Oncotarget. 2017;8(52):90477.
18. Jun IJ, Jo JY, Kim JI, Chin JH, Kim WJ, Kim HR, et al. Impact of anesthetic agents on overall and recurrence-free survival in patients undergoing esophageal cancer surgery: A retrospective observational study. Scientific Reports. 2017;7(1):14020.
19. Oh TK, Kim K, Jheon S, Lee J, Do SH, Hwang JW, et al. Long-Term Oncologic Outcomes for Patients Undergoing Volatile Versus Intravenous Anesthesia for Non-Small Cell Lung Cancer Surgery: A Retrospective Propensity Matching Analysis. Cancer Control. 2018;25(1):1073274818775360.
20. Zheng X, Wang Y, Dong L, Zhao S, Wang L, Chen H, et al. Effects of propofol-based total intravenous anesthesia on gastric cancer: a retrospective study. OncoTargets and therapy. 2018;11:1141.
21. Wu ZF, Lee MS, Wong CS, Lu CH, Huang YS, Lin KT, et al. Propofol-based Total Intravenous Anesthesia Is Associated with Better Survival Than Desflurane Anesthesia in Colon Cancer Surgery. Anesthesiology. 2018;129(5): 932-941.
22.Soltanizadeh S, Degett T H, Gögenur I. Outcomes of cancer surgery after inhalational and intravenous anesthesia: A systematic review. Journal of clinical anesthesia. 2017;42:19-25.
23. Wells GA, Shea B, O’Connell D, Petersen J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Department of Epidemiology and Community Medicine, University of Ottawa, Canada. www. ohr i. ca/programs/clinical_ epidemiology/oxford. htm.
24.Wells GA, Shea B, Higgins JP, Sterne J, Tugwell P, Reeves BC. Checklists of methodological issues for review authors to consider when including nonrandomized studies in systematic reviews. Res Synth Meth. 2013;4:63e77.
25.Valentine JC, Thompson SG. Issues relating to confounding and meta-analysis when including non-randomized studies in systematic reviews on the effects of interventions. Res Synth Meth. 2013;4:26e35.
26.Reeves BC, Higgins JPT, Ramsay C, Shea B, Tugwell P, Wells GA. An introduction
to methodological issues when including non-randomized studies in systematic reviews on the effects of interventions. Res Synth Meth. 2013;4:1e11.
27. Myles PS, Peyton P, Silbert B, Hunt J, Rigg JR, Sessler DI. Perioperative epidural analgesia for major abdominal surgery for cancer and recurrence-free survival: randomised trial. Bmj. 2011;342:d1491.
28.Wunsch H, Linde-Zwirble WT, Angus DC. Methods to adjust for bias and confounding in critical care health services research involving observational data. J Crit Care. 2006;21:1e7.v
29.Bradburn MJ, Clark TG, Love SB, Altman DG. Survival analysis Part III: multivariate data analysis e choosing a model and assessing its adequacy and fit. Br J Cancer. 2003;89:605e11.
30. Parsons LS. Reducing Bias in a Propensity Score Matched-Pair Sample Using Greedy Matching Techniques [EB/OL]. Seattle, WA: Ovation Research Group. Available from: http://www2.sas.com/proceedings/sugi26/p214-26.pdf. Accessed September 22, 2010.
31.Rosenbaum P R, Rubin D B. Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. The American Statistician. 1985;39(1): 33-38.
32. Woo JH, Baik HJ, Kim CH, Chung RK, Kim DY, Lee GY, et al. Effect of propofol and desflurane on immune cell populations in breast cancer patients: a randomized trial. Journal of Korean medical science. 2015;30(10):1503-1508.
33. Mitsuhata H, Shimizu R, Yokoyama MM. Suppressive effects of volatile anesthetics on cytokine release in human peripheral blood mononuclear cells. International journal of immunopharmacology. 1995;17(6):529-534.
34. Salo M, Pirttikangas C O, Pulkki K. Effects of propofol emulsion and thiopentone on T helper cell type-1/type‐2 balance in vitro. Anaesthesia. 1997;52(4):341-344.
35. Christopherson R, James KE, Tableman M, Marshall P, Johnson FE. Long-term survival after colon cancer surgery: a variation associated with choice of anesthesia. Anesthesia & Analgesia. 2008;107(1):325-332.
36. Coleman MP, Quaresma M, Berrino F, Lutz JM, De Angelis R, Capocaccia R, et al. Cancer survival in five continents: a worldwide population-based study (CONCORD). The lancet oncology. 2008;9(8):730-756.
37. Gupta G P, Massagué J. Cancer metastasis: building a framework. Cell. 2006;127(4):679-695.
38. Kaptchuk TJ. The double-blind, randomized, placebo-controlled trial: gold standard or golden calf? Journal of clinical epidemiology. 2001;54(6):541-549.
39. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. Bmj. 2011;343:d5928.